Cannabis consumers in legal states used to dream of one strain more than any other, but new data suggests they’re increasingly glued to something else.

Sales of the sativa hybrid strain Blue Dream have long reigned supreme in dispensaries across legal states, according to cannabis data firm BDS Analytics. It has, in fact, triumphed in Colorado every month since February of 2014, with similar stories unfolding in Washington and Oregon.

In 2015, however, BDS Analytics watched as the potent hybrid strain Gorilla Glue #4 began rising through the ranks in Oregon. In 2016, it finally surpassed Blue Dream in Oregon, selling $7,396,498 worth of flower compared to Blue Dream's $6,475,251.

“We have watched Blue Dream's dominance for years, and have wondered whether another strain would challenge its leading position,” states a press release from BDS Analytics. “It looks like we now have a serious competitor in Gorilla Glue #4.”

The strain’s sudden rise to power isn’t limited to Oregon.

While the strain didn’t appear in Colorado or Washington’s top 10 strains list until January 2016, its sales proceeded to gather strength month after month.

By October of 2016, Gorilla Glue #4 was the No. 2 strain in Washington State, with $940,000 in sales during that month. Its upward trajectory continued in November with $1 million in sales, as Blue Dream’s dropped to $1.5 million.  

Meanwhile, in Colorado, Gorilla Glue #4 claimed the No. 2 spot in September with $1.6 million in sales, before dipping into the middle of the pack in October, November and December. By the end of the year, Gorilla Glue #4 was the No. 4 strain in Colorado overall with $9,395,135 in sales compared to Blue Dream's gargantuan haul of $27,156,279.

Overall, Gorilla Glue #4 snagged second place among all channels in Colorado, Washington and Oregon in 2016, with $24,019,872 in sales compared to Blue Dream's $48,957,180.

“The tri-state trajectory — from just another strain to top contender — bodes well for Gorilla Glue #4's future in 2017,” states BDS Analytics. “Which strain will emerge triumphant by the end of 2017? We look forward to tracking this strain battle.”

[DisplayAd]